Genomic Characterization of Chondrosarcoma Reveals Potential Therapeutic Targets
These findings reinforce therapeutic efforts to target IDH signaling in chondrosarcoma, provide insight into varied subpopulation response to immune checkpoint inhibitors, and identify new potential therapeutic targets for clinical development in chondrosarcoma.
Authors
- Nathan W. Sweeney (ORCID: https://orcid.org/0000-0002-2317-6207)
- Candace L. Haddox (ORCID: https://orcid.org/0000-0003-4223-0632)
- Michael J. Wagner (ORCID: https://orcid.org/0000-0002-8812-1653)
- Erica Pimenta (ORCID: https://orcid.org/0000-0002-9684-6486)
- Binyam Yilma (ORCID: https://orcid.org/0009-0007-8845-5390)
- James L. Chen (ORCID: https://orcid.org/0000-0002-4095-5202)
- Melissa C. Stoppler
- Lee D. Cranmer (ORCID: https://orcid.org/0000-0002-7789-5442)
- Eleanor Y. Chen (ORCID: https://orcid.org/0000-0003-4372-7560)
- Elyse J. Brinkmann (ORCID: https://orcid.org/0000-0002-4489-8321)
- Elizabeth T. Loggers (ORCID: https://orcid.org/0000-0003-3432-0443)
- Robert W. Ricciotti (ORCID: https://orcid.org/0000-0001-9545-5507)
- J. Scott Roberts
- R J Berg
Institutions
- University of Washington (US)
- University of Washington Medical Center (US)
- Fred Hutch Cancer Center (US)
- Tempus Labs (United States) (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JCO Precision Oncology
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1200/po-24-00592
- Citations
- 5
- Primary Topic
- Bone Tumor Diagnosis and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 8.34